H2020Индивидуална стипендия2021–2023

MaCaROM · Mapping Cancer Response using Organoids and Mass cytometry

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-04-01 → 2023-03-31
Финансиране от ЕС: 191 149 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Органоидите от рак на гърдата, създадени от клетки на пациенти, се използват за проследяване на реакцията на тумора към различни лекарства. Това помага за избора на най-подходящото лечение за всеки пациент и подобрява шансовете за оцеляване.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Mapping Cancer Response using Organoids and Mass cytometry

Advances in breast cancer drug discovery are limited by the absence of a relevant research model. Cancer cell lines and mice are the most widely used models but they fail at recapitulating several cancer features including drug responses. Patient-derived organoids (PDOs) have been demonstrated to capture the main biological features of the primary tumor. Furthermore, PDOs recapitulate the patients’ response to anticancer treatment which makes them the new gold standard model in the study of cancer response to drugs. Using such a model to study cancer would be an unvaluable asset to better understand drug response and predict which drug should be used for each patient. This would improve cancer healthcare by increasing the overall survival of cancer patients, and improve the healthcare system by giving the best drug possible to each patient. Here, we created breast cancer PDOs in order to better understand drug responses of breast cancer patients. We used several quality controls to make sure that the generated PDOs recapitulate the main features of their tissue of origin and we studied them in order to better understand the correspondence between a tumor and its probability to be sensitive to a given drug treatment. We will then reference all these response data in order to make them available to clinicians so that it can be a new resource to help guide the treatment course of future cancer patients.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Breast cancer is the most common form of cancer in women and has a very variable prognosis. Efficacy of anticancer therapies is limited by intertumor and intratumor heterogeneity. To take these into account, tumor models should recapitulate native tumor heterogeneity and should be analysed at the single-cell level. Here, we propose to take advantage of the conserved heterogeneity of breast cancer patient-derived organoids in order to analyze their response to 45 FDA-approved drugs. These responses will be mapped in a single-cell atlas of sensitivities using mass cytometry, and the use of this atlas will be assessed for the prediction of drug sensitivity in future patient tumors and to guide treatment. We plan on exploring the best hits of this screening using imaging mass cytometry to have a spatial view of the evolution of the tumor ecosystem over time after drug treatment. This should positively impact patient treatment and survival and, more broadly, could lead to the new concept of “mapping-based precision medicine”. This project will also uncover the biology of resistance to drug treatments at unprecedented resolution. The study of the different cellular populations composing breast tumors, and their interactions, will lead to a better understanding of the tumor ecosystem and to the identification of therapies targeting specific cellular populations that could trigger tumor demise.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITAT ZURICH · ZurichКоординаторШвейцария